CCBIO seminar: Ole Frithjof Norheim
Can biomarkers improve priority setting for new, expensive cancer drugs?
Main content
Ole Frithjof Norheim
Department of Global Public Health and Primary Care, Global Health Priorities, University of Bergen
This talk will discuss how reimbursement decisions for new expensive cancer drugs are made in Norway and UK. Cost-effectiveness and severity of disease are two important criteria. These can vary significantly by patient heterogeneity in prognosis and treatment effect. Adjuvant Trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive breast cancer is used as a model for discussion of subgroup analysis with respect to priority setting and cost-effectiveness thresholds. Implications for newer drugs will also be discussed.
Chairperson: Roger Strand, CCBIO
